Diagnosis and Management of Anaplastic Thyroid Cancer

Ashish Chintakuntlawar, Robert L. Foote, Jan Kasperbauer, Keith C. Bible

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.

Original languageEnglish (US)
Pages (from-to)269-284
Number of pages16
JournalEndocrinology and Metabolism Clinics of North America
Volume48
Issue number1
DOIs
StatePublished - Mar 1 2019

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Chemoradiotherapy
Therapeutics
Mutation
Survival
Population
Anaplastic Thyroid Carcinoma

Keywords

  • Anaplastic thyroid cancer
  • Chemoradiotherapy
  • Multimodality therapy
  • Systemic therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Diagnosis and Management of Anaplastic Thyroid Cancer. / Chintakuntlawar, Ashish; Foote, Robert L.; Kasperbauer, Jan; Bible, Keith C.

In: Endocrinology and Metabolism Clinics of North America, Vol. 48, No. 1, 01.03.2019, p. 269-284.

Research output: Contribution to journalReview article

@article{fdcb183cd908418bbbdb0bb882431d0b,
title = "Diagnosis and Management of Anaplastic Thyroid Cancer",
abstract = "Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.",
keywords = "Anaplastic thyroid cancer, Chemoradiotherapy, Multimodality therapy, Systemic therapy",
author = "Ashish Chintakuntlawar and Foote, {Robert L.} and Jan Kasperbauer and Bible, {Keith C.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.ecl.2018.10.010",
language = "English (US)",
volume = "48",
pages = "269--284",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Diagnosis and Management of Anaplastic Thyroid Cancer

AU - Chintakuntlawar, Ashish

AU - Foote, Robert L.

AU - Kasperbauer, Jan

AU - Bible, Keith C.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.

AB - Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.

KW - Anaplastic thyroid cancer

KW - Chemoradiotherapy

KW - Multimodality therapy

KW - Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=85060885342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060885342&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2018.10.010

DO - 10.1016/j.ecl.2018.10.010

M3 - Review article

VL - 48

SP - 269

EP - 284

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - 1

ER -